J.D. Wolchok

Discipline

Economies et finances (1)

Type de document

Articles (7) Recensions (1)

Co-auteur

Date

Source

Mot-clé

cancer (4) Treatment (4) Cancer (4) Patients (4) Immunotherapy (4) Cancer (4) Patients (4) Immunotherapy (4) thérapie (3) protéine (3) analyse (3) survie (3) Tumors (3) Therapeutics (3) Survival (3) Melanoma (3) Analysis (3) Europe (2) ligne (2) taux (2) Europe (2) Inhibitors (2) T cells (2) Months (2) Mice (2) Human beings (2) Evidence (2) Europe (2) Cells (2) Regions (2)

Documents écrit par J.D. Wolchok (7) | parle de J.D. Wolchok (0)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
K. Homicsko et al. (5 mai 2022)
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.
R. Zappasodi et al.
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
H. Wang et al.
Classification of current anticancer immunotherapies.
L. Galluzzi et al. (2014)
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
J.J. Luke et al. (2013)
Defining the critical hurdles in cancer immunotherapy.
B.A. Fox et al. (2011)
Frequent MAGE mutations in human melanoma.
O.L. Caballero et al. (2010)